Haesuk Park

Haesuk Park, Ph.D.

Associate Professor

Department: Pharmaceutical Outcomes & Policy
Business Phone: (352) 273-6261
Business Email: haesukpark@ufl.edu

About Haesuk Park

Haesuk Park, Ph.D., is an Associate Professor in the Department of Pharmaceutical Outcomes and Policy. She received her Bachelor and Master in Pharmacy from South Korea, and her Ph.D. at The University of Texas at Austin, College of Pharmacy, Health Outcomes & Pharmacy Practice. Her research centers on economic and health outcomes studies of medications and pharmaceutical care services as well as policy associated with the use of pharmaceuticals. She is passionate about investigating questions related to health policy in vulnerable populations and, particularly, how a policy affects access to care, the quality and cost of health care, and ultimately health outcomes.

Teaching Profile

Courses Taught
2014-2024
PHA5267 Prin Pharm-Economics
2014-2024
PHA6935 Selected Topics in Pharmacy
2014-2018,2020-2023
PHA6910 Supervised Research
2014-2018,2020-2024
PHA7980 Research for Doctoral Dissertation
2014-2018,2020-2024
PHA7979 Advanced Research
2019-2021
PHA6940 Supervised Teaching
2015,2018-2024
PHA6265 Introduction to Pharmaceutical Outcomes and Policy I
2014-2021
PHA6937 Topics in Pharmaceutical Administration
2014-2017,2019-2021
PHA6936 Advanced Topics in Pharmaceutical Sciences
2015-2018,2020-2023,2023
PHA6971 Research for Master’s Thesis
2014,2018-2019
PHA6938 Research Seminar
2015,2017
PHA6266 Introduction to Pharmaceutical Outcomes and Policy II
2016
PHA5933 Select Top Pharmacy
2014-2015
PHA6279 Pharmaceutical Outcomes and Policy Seminar
2014
PHA6805 Applied Data Interpretation and Reporting of Findings in Pharmacy
2022-2024
PHA5784C Pt Care 4: GI and Renal

Research Profile

In recent years, clinical focus of Dr. Park’s research has centered on patients with hepatitis C virus (HCV) infection, a research area with growing intensity and breadth due to the increasing awareness of the disease burden and the continuing development of new treatments. In 2018, Park received a 5-year NIH/National Institute on Drug Abuse (NIDA) K01 to build a research program in the area of HCV and health policy for individuals with substance use disorders. Currently, she also collaborated on a NIH/NHLBI R01 project to evaluate the impact of the pharmacist-led telehealthcare medication therapy management to change health outcomes in adolescents and young adults with asthma (MATCH).

Her research has received a number of awards and recognition by the professional community such as the Best New Investigator Presentation Award at the International Society for Pharmaceutical Outcomes Research (ISPOR), Best Paper Award in the Economic, Social & Administrative Sciences at the American Pharmacists Association (APhA) Annual Meeting, and the 2015 University of Florida Excellence Award for Assistant Professors. Her research interests include Pharmacoeconomics and health policy research, economic and health outcomes evaluation and meta-analysis.

Open Researcher and Contributor ID (ORCID)

0000-0003-3299-8111

Publications

2024
Comparative effectiveness of sacubitril/valsartan versus angiotensin receptor blockers in patients with heart failure with preserved ejection fraction: A real-world study
American Journal of Health-System Pharmacy. [DOI] 10.1093/ajhp/zxae053.
2024
Elucidating the association between direct-acting antivirals and Parkinson’s disease in patients with hepatitis C virus infection
Parkinsonism & Related Disorders. 123 [DOI] 10.1016/j.parkreldis.2024.106557.
2023
Association between treatment of hepatitis C virus and risk of cardiovascular disease among insured patients with the virus in the United States
Pharmacoepidemiology and Drug Safety. 32(10):1142-1151 [DOI] 10.1002/pds.5651. [PMID] 37278688.
2023
Clinician barriers, perceptions, and practices in treating patients with hepatitis C virus and substance use disorder in the United States
Preventive Medicine Reports. 32 [DOI] 10.1016/j.pmedr.2023.102138. [PMID] 36865395.
2023
Comparative effectiveness and safety of direct oral anticoagulants versus warfarin among patients with recurrent venous thromboembolism
Clinical and Translational Science. 16(6):946-954 [DOI] 10.1111/cts.13510. [PMID] 36891985.
2023
Comparative effectiveness and safety of extended anticoagulant therapy among Medicare beneficiaries with venous thromboembolism
Clinical and Translational Science. 16(1):128-139 [DOI] 10.1111/cts.13433. [PMID] 36200137.
2023
Comparative effectiveness of pegfilgrastim biosimilars vs originator for prevention of febrile neutropenia: A retrospective cohort study.
Journal of managed care & specialty pharmacy. 29(2):119-127 [DOI] 10.18553/jmcp.2023.29.2.119. [PMID] 36705287.
2023
Comparative effectiveness of sodium‐glucose cotransporter‐2 inhibitors among patients with heart failure with preserved ejection fraction
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 43(10):1024-1031 [DOI] 10.1002/phar.2853.
2023
Disparities in Access to Hepatitis C Treatment Among Arizona Medicaid Beneficiaries With Chronic Hepatitis C
Medical Care. 61(2):81-86 [DOI] 10.1097/mlr.0000000000001801.
2023
Economic Impact of Universal Hepatitis C Virus Testing for Middle-Aged Adults Who Inject Drugs
American Journal of Preventive Medicine. 64(1):96-104 [DOI] 10.1016/j.amepre.2022.08.016. [PMID] 36257884.
2023
Hepatitis C Cascade of Care in the Direct-Acting Antivirals Era: A Meta-Analysis
American Journal of Preventive Medicine. 65(6):1153-1162 [DOI] 10.1016/j.amepre.2023.06.016. [PMID] 37380088.
2023
Impact of Direct-acting Antivirals on Hepatocellular Carcinoma and Mortality Among Medicaid Beneficiaries With Hepatitis C
Medical Care. 61(8):505-513 [DOI] 10.1097/mlr.0000000000001870.
2023
Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: A cross-sectional study in the United States.
Journal of managed care & specialty pharmacy. 29(7):721-731 [DOI] 10.18553/jmcp.2023.29.7.721. [PMID] 37404074.
2023
Oral fluoroquinolones and risk of aortic aneurysm or dissection: A nationwide population‐based propensity score‐matched cohort study
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 43(9):883-893 [DOI] 10.1002/phar.2841.
2023
Risk of Fractures With Concomitant Use of Calcium Channel Blockers and Selective Serotonin Reuptake Inhibitors
Annals of Pharmacotherapy. [DOI] 10.1177/10600280231218286.
2023
Trajectories of adherence to extended treatment with warfarin and risks of recurrent venous thromboembolism and major bleeding.
Research and practice in thrombosis and haemostasis. 7(3) [DOI] 10.1016/j.rpth.2023.100131. [PMID] 37159747.
2023
Trajectories of Oral Anticoagulation Adherence and Associated Clinical Outcomes During Long-Term Anticoagulation Among Medicare Beneficiaries With Venous Thromboembolism
Annals of Pharmacotherapy. 57(12):1349-1360 [DOI] 10.1177/10600280231155489.
2023
Trajectories of Preexposure Prophylaxis Adherence Among Commercially Insured Individuals
Clinical Infectious Diseases. [DOI] 10.1093/cid/ciad756.
2023
Trends in Recommended Screening and Monitoring Tests for Users of HIV Pre-Exposure Prophylaxis Before and During the COVID-19 Pandemic
AJPM Focus. 2(4) [DOI] 10.1016/j.focus.2023.100134. [PMID] 37790950.
2023
Trends, characteristics, race, and ethnicity associated with nonadherence to antidepressants among breast cancer survivors with depression.
Journal of managed care & specialty pharmacy. 29(4):431-445 [DOI] 10.18553/jmcp.2023.29.4.431. [PMID] 36989452.
2022
Comparative Safety and Effectiveness of Aldosterone Antagonists Versus Beta-Blockers as Fourth Agents in Patients With Apparent Resistant Hypertension
Hypertension. 79(10):2305-2315 [DOI] 10.1161/hypertensionaha.122.19280.
2022
Comparative Safety of Sleeve Gastrectomy and Roux-en-Y: A Propensity Score Analysis.
World journal of surgery. 46(11):2715-2724 [DOI] 10.1007/s00268-022-06664-0. [PMID] 35840690.
2022
Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolism
Journal of Internal Medicine. 291(6):877-885 [DOI] 10.1111/joim.13462.
2022
Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: group‐based multi‐trajectory models
Addiction. 117(7):1982-1997 [DOI] 10.1111/add.15857.
2022
Effectiveness and Safety of Extended Oral Anticoagulant Therapy in Patients with Venous Thromboembolism: A Retrospective Cohort Study.
Clinical pharmacology and therapeutics. 112(1):133-145 [DOI] 10.1002/cpt.2611. [PMID] 35420702.
2022
Evaluation of machine learning algorithms for predicting direct-acting antiviral treatment failure among patients with chronic hepatitis C infection.
Scientific reports. 12(1) [DOI] 10.1038/s41598-022-22819-4. [PMID] 36302828.
2022
Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United States
JCO Oncology Practice. 18(1):e163-e174 [DOI] 10.1200/op.21.00140.
2022
Machine learning algorithms for predicting direct‐acting antiviral treatment failure in chronic hepatitis C: An HCV‐TARGET analysis
Hepatology. 76(2):483-491 [DOI] 10.1002/hep.32347. [PMID] 35034373.
2022
Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis
Clinical Journal of the American Society of Nephrology. 17(6):851-860 [DOI] 10.2215/cjn.14361121.
2022
Norepinephrine reuptake inhibitors and risk of antihypertensive treatment intensification and major adverse cardiovascular events in patients with stable hypertension and depression
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 42(6):472-482 [DOI] 10.1002/phar.2686.
2022
Patient out-of-pocket and payer costs for pegfilgrastim originator vs biosimilars as primary prophylaxis of febrile neutropenia in the first cycle among a commercially insured population.
Journal of managed care & specialty pharmacy. 28(7):795-802 [DOI] 10.18553/jmcp.2022.28.7.795. [PMID] 35737859.
2022
Resource Over-Utilization in Hospitalized Patients With Uncomplicated Skin and Soft Tissue Infections.
Journal of pharmacy practice. 35(5):675-679 [DOI] 10.1177/08971900211000216. [PMID] 33752488.
2022
Risk of Obstructive Sleep Apnea in Adults with Resistant Hypertension
Pharmacoepidemiology. 1(1):26-32 [DOI] 10.3390/pharma1010003.
2022
Trends in the Management of Headache Disorders in US Emergency Departments: Analysis of 2007-2018 National Hospital Ambulatory Medical Care Survey Data.
Journal of clinical medicine. 11(5) [DOI] 10.3390/jcm11051401. [PMID] 35268492.
2022
Utilization of chronic lung disease treatment before the respiratory syncytial virus season as palivizumab prophylaxis qualifier in the American Academy of Pediatrics Guidelines.
European journal of pediatrics. 181(2):841-845 [DOI] 10.1007/s00431-021-04233-6. [PMID] 34365543.
2021
Calibration of Chronic Lung Disease Severity as a Risk Factor for Respiratory Syncytial Virus Hospitalization.
Journal of the Pediatric Infectious Diseases Society. 10(3):317-325 [DOI] 10.1093/jpids/piaa107. [PMID] 32978942.
2021
Cascade of Hepatitis C Virus Care Among Patients With Substance Use Disorders.
American journal of preventive medicine. 61(4):576-584 [DOI] 10.1016/j.amepre.2021.04.013. [PMID] 34210584.
2021
Changes in Schedule II oral opioid volume dispensed in a private health plan following Florida’s Acute Pain Opioid Restriction Law.
Journal of managed care & specialty pharmacy. 27(6):779-784 [DOI] 10.18553/jmcp.2021.27.6.779. [PMID] 34057389.
2021
Direct‐Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C
Hepatology Communications. 5(2):203-216 [DOI] 10.1002/hep4.1634. [PMID] 33553969.
2021
Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 41(9):710-721 [DOI] 10.1002/phar.2610.
2021
Health-Related Quality of Life and Health Utilities of Mild, Moderate, and Severe Asthma: Evidence from the Medical Expenditure Panel Survey
Journal of Asthma and Allergy. Volume 14:929-941 [DOI] 10.2147/jaa.s316278.
2021
Non-steroidal anti-inflammatory drug-associated acute kidney injury: does short-term NSAID use pose a risk in hospitalized patients?
European journal of clinical pharmacology. 77(9):1409-1417 [DOI] 10.1007/s00228-021-03121-0. [PMID] 33772627.
2021
Self-reported hepatitis C(HCV) testing among people living with human immunodeficiency virus (PLWH)
Heliyon. 7(8) [DOI] 10.1016/j.heliyon.2021.e07727. [PMID] 34409188.
2021
Surveillance of patients with cirrhosis remains suboptimal in the United States
Journal of Hepatology. 75(4):856-864 [DOI] 10.1016/j.jhep.2021.04.042.
2021
The Impact of Direct‐Acting Antiviral Therapy on End‐Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders
Hepatology. 74(2):566-581 [DOI] 10.1002/hep.31732. [PMID] 33544904.
2021
The use of all-oral direct-acting antivirals in hepatitis C virus-infected patients with substance use disorders.
Journal of managed care & specialty pharmacy. 27(7):873-881 [DOI] 10.18553/jmcp.2021.27.7.873. [PMID] 34185563.
2021
Trends in Sexually Transmitted Infections in United States Ambulatory Care Clinics from 2005-2016.
Journal of clinical medicine. 11(1) [DOI] 10.3390/jcm11010071. [PMID] 35011812.
2021
Trends in Use of Granulocyte Colony-Stimulating Factor Following Introduction of Biosimilars Among Adults With Cancer and Commercial or Medicare Insurance From 2014 to 2019.
JAMA network open. 4(11) [DOI] 10.1001/jamanetworkopen.2021.33474. [PMID] 34812849.
2021
US national trends in bariatric surgery: A decade of study.
Surgery. 170(1):13-17 [DOI] 10.1016/j.surg.2021.02.002. [PMID] 33714616.
2020
<p>Medical Costs and Productivity Loss Due to Mild, Moderate, and Severe Asthma in the United States</p>
Journal of Asthma and Allergy. Volume 13:545-555 [DOI] 10.2147/jaa.s272681.
2020
A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA.
Digestive diseases and sciences. 65(5):1520-1528 [DOI] 10.1007/s10620-019-05869-z. [PMID] 31598919.
2020
Comparative effectiveness and safety of apixaban versus warfarin in patients with venous thromboembolism.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 77(3):188-195 [DOI] 10.1093/ajhp/zxz307. [PMID] 31974557.
2020
Comparative Effectiveness and Safety of Direct-acting Oral Anticoagulants and Warfarin in Patients with Venous Thromboembolism and Active Cancer: An Observational Analysis.
Clinical therapeutics. 42(9):e161-e176 [DOI] 10.1016/j.clinthera.2020.06.022. [PMID] 32768247.
2020
Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection
Digestive Diseases and Sciences. 65(11):3159-3174 [DOI] 10.1007/s10620-019-06037-z. [PMID] 31938995.
2020
Immune Checkpoint Inhibitors and Immune-Related Adverse Events in Patients With Advanced Melanoma: A Systematic Review and Network Meta-analysis.
JAMA network open. 3(3) [DOI] 10.1001/jamanetworkopen.2020.1611. [PMID] 32211869.
2020
Impact of hepatitis C virus treatment on the risk of non‐hepatic cancers among hepatitis C virus‐infected patients in the US
Alimentary Pharmacology & Therapeutics. 52(10):1592-1602 [DOI] 10.1111/apt.16081. [PMID] 32931606.
2020
Proton pump inhibitors and risk of liver cancer and mortality in patients with chronic liver disease: a systematic review and meta-analysis
European Journal of Clinical Pharmacology. 76(6):851-866 [DOI] 10.1007/s00228-020-02854-8. [PMID] 32172363.
2020
Twelve‐year trends in pharmacologic treatment of type 2 diabetes among patients with heart failure in the United States
Diabetes, Obesity and Metabolism. 22(4):705-710 [DOI] 10.1111/dom.13949.
2020
Usability of encounter data for Medicaid comprehensive managed care vs traditional Medicaid fee‐for‐service claims among pregnant women
Pharmacoepidemiology and Drug Safety. 29(1):30-38 [DOI] 10.1002/pds.4923.
2019
Cardiovascular outcomes of sodium glucose cotransporter‐2 inhibitors in patients with type 2 diabetes
Diabetes, Obesity and Metabolism. 21(1):28-36 [DOI] 10.1111/dom.13477.
2019
Comparative Effectiveness and Safety of Ticagrelor versus Prasugrel in Patients with Acute Coronary Syndrome: A Retrospective Cohort Analysis
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 39(9):912-920 [DOI] 10.1002/phar.2311.
2019
Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis
Lancet Haematology. E20-E28 [DOI] 10.1016/52352-3026(18)30191-1.
2019
Impact of All‐Oral Direct‐Acting Antivirals on Clinical and Economic Outcomes in Patients With Chronic Hepatitis C in the United States
Hepatology. 69(3):1032-1045 [DOI] 10.1002/hep.30303. [PMID] 30289989.
2019
Nonalcoholic fatty liver disease increases risk of incident advanced chronic kidney disease: a propensity‐matched cohort study
Journal of Internal Medicine. 286(6):711-722 [DOI] 10.1111/joim.12964. [PMID] 31359543.
2019
The association between proton pump inhibitor use and the risk of tuberculosis: A case‐control study
Pharmacoepidemiology and Drug Safety. 28(6):830-839 [DOI] 10.1002/pds.4773.
2018
Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists
Cardiovascular Diabetology. 17(1) [DOI] 10.1186/s12933-018-0746-4. [PMID] 30016946.
2018
Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006–2015)
BMC Nephrology. 19(1) [DOI] 10.1186/s12882-018-1119-7. [PMID] 30413150.
2017
Impact of a Telephonic Outreach Program on Medication Adherence in Medicare Advantage Prescription Drug (Mapd) Plan Beneficiaries
Journal of the American Pharmacists Association. 57(1):62+-66.e2 [DOI] 10.1016/j.japh.2016.07.006.
2017
The Value of Cure Associated With Treating Treatment-Naive Chronic Hepatitis C Genotype 1: Are the New All-Oral Regimens Good Value to Society?
Liver International. 37(5):662-668 [DOI] 10.1111/liv.13298.
2016
Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden.
Gastroenterology. 150(7):1599-1608 [DOI] 10.1053/j.gastro.2016.02.039. [PMID] 26924097.
2015
Direct Medical Costs and Utilization of Health Care Services to Treat Pneumonia in the United States: An Analysis of the 2007-2011 Medical Expenditure Panel Survey.
Clinical therapeutics. 37(7):1466-1476.e1 [DOI] 10.1016/j.clinthera.2015.04.013. [PMID] 26001310.
2014
Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Journal of managed care & specialty pharmacy. 20(8):862-76 [DOI] 10.18553/jmcp.2014.20.8.862. [PMID] 25062080.

Grants

Sep 2023 ACTIVE
Assessing performance of a Hepatitis C Emergency Department (HepC-END) Screening Tool
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDA
Jun 2023 ACTIVE
Longitudinal impact of narcolepsy and cardiovascular disease: A claims-based study
Role: Co-Investigator
Funding: SLEEP RESEARCH SOCIETY FOUNDATION
Apr 2020 – Apr 2023
Trajectories of apixaban for extended treatment of recurrent venous thromboembolism: a retrospective cohort study
Role: Principal Investigator
Funding: BRISTOL MYERS SQUIBB CO
Apr 2019 – Aug 2023
A Behavioral Economic Intervention to Reduce Marijuana Use in Truant Youth
Role: Other
Funding: NATL INST OF HLTH NIDA
May 2018 ACTIVE
Improving Medication Adherence with Telehealthcare Medication Therapy Management to Change Health Outcomes in Adolescents and Young Adults with Asthma (MATCH)
Role: Principal Investigator
Funding: NEMOURS CHILDRENS CLINIC via NATL INST OF HLTH NHLBI
May 2018 – Apr 2023
Medicaid Prior Authorization Policies for Chronic Hepatitis C Treatment in Vulnerable Populations
Role: Principal Investigator
Funding: NATL INST OF HLTH NIDA
Jun 2016 – Jun 2018
Work Order No. US201601
Role: Principal Investigator
Funding: PROTEUS DIGITAL HEALTH INC
Apr 2014 – Mar 2017
HCV Quality-Adjusted Cost of Care (Work Order #5)
Role: Principal Investigator
Funding: GILEAD SCIENCES

Contact Details

Phones:
Business:
(352) 273-6261
Emails:
Business:
haesukpark@ufl.edu
Addresses:
Business Mailing:
PO Box 100496
GAINESVILLE FL 32610
Business Street:
1225 CENTER DR
HPNP 3325
GAINESVILLE FL 326103007

Recent news

International Day of Women in Science

The University of Florida College of Pharmacy celebrates women advancing the pharmaceutical sciences during the fifth International Day of Women and Girls in Science on Feb. 11. Five female faculty…